FLUCLOXACILLIN

DESCRIPTION
Semisynthetic penicillin and penicillinase resistant. Bactericidal and inhibits the biosynthesis of cell wall mucoproteins. Reliably absorbed by oral route. Major route of excretion is renal.

USE
Narrow spectrum antibiotic used in the treatment of gram-positive organisms, especially penicillinase producing staph aureus and penicillin sensitive staph epidermidis.

PRESENTATION
250mg/vial, 500mg/vial
250mg/5ml powder for suspension

DOSE
ORAL 25mg/kg/dose regardless of age or gestation
IV 50mg/kg/dose (100mg/kg/dose can be prescribed for treatment of staphylococcal meningitis or cerebral abcess.)

<table>
<thead>
<tr>
<th>Postnatal age</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-7 days</td>
<td>12hrly</td>
</tr>
<tr>
<td>&gt;7 days</td>
<td>8hrly</td>
</tr>
</tbody>
</table>

ROUTE
IV injection
Oral

RECONSTITUTION
Add 4.8ml water for injection to 250mg vial to make a 50mg/ml solution.
Add 4.6ml water for injection to 500mg vial to make a 100mg/ml solution.

ADMINISTRATION
Slow IV bolus injection using proximal IV bung.

STORAGE
Discard unused portion.

MONITORING
Irritating to veins, observe IV site for signs of extravasation.

ADVERSE EFFECT
Rare.
1. Nausea, vomiting, diarrhea, dyspepsia
2. Rashes. May develop more than 48 hours after treatment.
3. Interstitial nephritis
4. Cholestatic hepatitis has been reported following prolonged therapy. May manifest up to 6 weeks after therapy and may last for months.
5. Bone marrow depression. Rare. Reversible after discontinuation of therapy. Believed to be hypersensitivity phenomena.
CAUTION

Dose may need modification in patients with renal failure as it is excreted predominantly via kidneys.

SOLUTION COMPATIBILITY

5% dextrose, 10% dextrose, 0.9% sodium chloride

INCOMPATIBILITY

Amikacin, gentamicin, kanomycin.

REFERENCE


